Home » Stocks » MITO

Stealth BioTherapeutics Corp. (MITO)

Stock Price: $1.43 USD 0.03 (2.14%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $1.34 -0.09 (-6.29%) Jul 23, 7:29 PM
Market Cap 81.57M
Revenue (ttm) 21.09M
Net Income (ttm) -57.46M
Shares Out 57.04M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $1.43
Previous Close $1.40
Change ($) 0.03
Change (%) 2.14%
Day's Open 1.40
Day's Range 1.33 - 1.45
Day's Volume 243,171
52-Week Range 1.06 - 2.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Stealth BioTherapeutics (MITO) has been struggling lately, but the selling pressure may be coming to an end soon.

2 weeks ago - Zacks Investment Research

BOSTON, July 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

2 weeks ago - PRNewsWire

Penny stocks see momentum as DogeCoin and other crypto's rise in value; here's 3 to watch The post Top Penny Stocks to Buy? 3 to Watch if You Like DogeCoin appeared first on Penny Stocks to Buy, Picks, ...

Other stocks mentioned: BOXL, IDEX
1 month ago - PennyStocks

The European Medicines Agency (EMA) has granted orphan drug designation to Stealth BioTherapeutics Corp's (NASDAQ: MITO) elamipretide for Barth syndrome, an ultra-rare genetic condition. Barth syndrome ...

1 month ago - Benzinga

BOSTON, June 1, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

1 month ago - PRNewsWire

BOSTON, May 28, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

1 month ago - PRNewsWire

BOSTON, May 18, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies fo...

2 months ago - PRNewsWire

Stealth BioTherapeutics Corp (NASDAQ: MITO) has reached an agreement with Morningside Ventures for Morningside to provide $30 million in additional payments to the Company during 2021 under its existing...

2 months ago - Benzinga

BOSTON, May 17, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

2 months ago - PRNewsWire

BOSTON, May 17, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

2 months ago - PRNewsWire

BOSTON, May 13, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

2 months ago - PRNewsWire

BOSTON, May 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

2 months ago - PRNewsWire

Will these 3 penny stocks be on your Thursday morning watchlist? The post Top Penny Stocks For Your Thursday Morning Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other stocks mentioned: LKCO, PRPO
2 months ago - PennyStocks

BOSTON, May 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies fo...

2 months ago - PRNewsWire

BOSTON, April 28, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies...

2 months ago - PRNewsWire

BOSTON, April 26, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies...

2 months ago - PRNewsWire

BOSTON, April 6, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...

3 months ago - PRNewsWire

BOSTON, March 31, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

3 months ago - PRNewsWire

BOSTON, March 16, 2021 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for d...

4 months ago - PRNewsWire

BOSTON, March 2, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies f...

4 months ago - PRNewsWire

BOSTON, Feb. 23, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies f...

5 months ago - PRNewsWire

BOSTON, Jan. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

6 months ago - PRNewsWire

BOSTON, Jan. 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

6 months ago - PRNewsWire

BOSTON, Dec. 9, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

7 months ago - PRNewsWire

BOSTON, Nov. 24, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercia...

8 months ago - PRNewsWire

Stealth BioTherapeutics (MITO) CEO Reenie McCarthy on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

BOSTON, Nov. 5, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

8 months ago - PRNewsWire

BOSTON, Nov. 4, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

8 months ago - PRNewsWire

BOSTON, Oct. 30, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies f...

8 months ago - PRNewsWire

BOSTON, Oct. 19, 2020 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for di...

9 months ago - PRNewsWire

BOSTON, Sept. 23, 2020 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for d...

10 months ago - PRNewsWire

BOSTON, Sept. 10, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

10 months ago - PRNewsWire

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q2 2020 Earnings Call Transcript

11 months ago - Seeking Alpha

BOSTON, May 26, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

1 year ago - PRNewsWire

As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).

1 year ago - Zacks Investment Research

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Stealth BioTherapeutics Corp. (NASDAQ: MITO) stock more than doubled on Tuesday after the company announced a critical update from the U.S.

1 year ago - 24/7 Wall Street

Shares of Stealth BioTherapeutics MITO, -63.94% tumbled 63% after it said a late-stage trial for its investigational treatment of primary mitochondrial myopathy, a muscular disease caused by genetic mut...

1 year ago - Market Watch

Stealth BioTherapeutics Corp. (NASDAQ: MITO) shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with primary mitochondrial myopathy.

1 year ago - 24/7 Wall Street

About MITO

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's heredit... [Read more...]

Industry
Biotechnology
IPO Date
Feb 15, 2019
Stock Exchange
NASDAQ
Ticker Symbol
MITO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for MITO stock is "Buy." The 12-month stock price forecast is 3.25, which is an increase of 127.27% from the latest price.

Price Target
$3.25
(127.27% upside)
Analyst Consensus: Buy